Yeah, with drugs.

Um, [laughs] uh, we, we're interested in the, uh, non-intravascular imaging.

And, uh, we have a revolution in computed tomography, uh, particularly with the advent of photon counting computed tomography, which now is, is not a very big installed base, but it has got to take over because it resolves so many problems.

Lower doses, um, see through the calcium, less bloom artifacts, so we can look into the place that's been stented previously.

Uh, and for me, very exciting, with the photon counting CT, you get spectral information that's completely wiped out from the conventional CT.

So for the next five to seven years, I think we're gonna be learning about non-invasive ways of characterizing plaques with much greater rigor and intensity than the traditional intravascular methods.

So I think we're gonna be able to plan invasive strategies and target lesions based on far more than just the percent stenosis.

Are you also optimistic in terms of, uh, metabolic pathways and, uh, uh, drug targets that we have, or do you see that, uh, there is still, uh, not-